Life Biosciences in Boston has treated the first participant in a gene therapy trial designed to partially reprogram aged cells, a “reverse aging” approach aimed at restoring youthful cellular behavior without full reversion to a stem-cell-like state. The trial targets glaucoma, using activation of three genes intended to promote regeneration of optic-nerve neurons. The study is positioned as a safety-first clinical test, reflecting field concerns about the risk of malignant transformation seen in parts of preclinical partial reprogramming research. The eye is being used as the initial organ system because researchers expect lower systemic risk than in interventions that broadly remodel other tissues. The step marks a high-visibility moment for rejuvenation biology: moving from preclinical validation into human dosing for a disease setting where neural regeneration could be therapeutically meaningful.